Psychedelic Drug Companies vs. Pot Stocks

Posted On Sep 28, 2021 By Addison Wiggin

While the cannabis markets are worth $20 to $30 billion, “the markets for psychedelics are vastly larger.” Remember, Cybin isn’t pushing psilocybin for recreational use. It’s specifically interested in using the chemical as a treatment for mental illnesses such as depression and addiction. As Cybin CEO Doug Drysdale told us yesterday, he estimates that “the total addressable market is something like $300 billion annually.” Needless to say, that kind of profit potential has persuaded more companies to start looking at psychedelic drugs.

Subscribe to Platinum Reserve Today!

From blue chips to penny stocks, income plays to growth opportunities, commodities to techs, ETFs to OTCs, bonds to options — the Agora Financial Platinum Reserve covers it all. You simply cannot find a more comprehensive source of investment analysis and recommendations.

Subscribe Today!